Allergy Therapeutics plc specializes in the research, development, and commercialization of allergy treatments and diagnostics. The company's product portfolio includes both subcutaneous (injectable) and sublingual (oral) immunotherapies designed to treat the underlying immunological causes of allergies rather than merely alleviating symptoms. Key commercial products include Pollinex Quattro, Oralvac, and Venomil, which are sold across major European markets such as Germany, Austria, Spain, and the UK. The company's clinical pipeline features novel candidates like Grass MATA MPL and a virus-like particle (VLP) peanut allergy vaccine. Formed as a spin-out from SmithKline Beecham, the company operates state-of-the-art manufacturing facilities in the UK and distributes its products globally through direct subsidiaries and distribution agreements.
